Boswellia AKBA / Frankincense High-Potency
Boswellia serrata (AKBA-enriched)
AKBA (acetyl-keto-beta-boswellic acid), the most potent fraction of Boswellia, crosses the blood-brain barrier and has shown remarkable activity against glioblastoma brain tumours. AKBA inhibits 5-LOX and VEGF, reduces tumour oedema, and is used as standard adjunct in German integrative oncology for brain cancers. H15 (standardised Boswellia extract) significantly reduces steroid dependency in brain cancer patients.
Medicinal Properties
Cancer Types Studied
Recommended Dosage
400–1200 mg AKBA-enriched Boswellia (30% AKBA) daily.
Preparations
AKBA-Standardised Extract
400–1200 mg Boswellia extract standardised to 30% AKBA daily. Specifically valuable for brain tumour patients on radiotherapy.
NIH / PubMed Research
Links open on PubMed (National Library of Medicine). Research is ongoing — results may not reflect clinical use.
Cautions & Interactions
- Monitor if on corticosteroids — may reduce steroid dose requirement
- Standard Boswellia has very low AKBA — must verify AKBA standardisation
- May interact with anti-inflammatory medications
- Generally very well-tolerated
Related Herbs
Informational only. Not medical advice. Consult your healthcare provider before use.